Ensitrelvir and Apixaban: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Aug 8, 2026 · Source data updated Jul 11, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Apixaban
Ensitrelvir
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Apixaban (Eliquis) is a blood thinner. Ensitrelvir is an antiviral used for COVID. The problem is that ensitrelvir slows down two of the body's normal ways of clearing apixaban out of your system. When that clearance slows down, apixaban can build up to higher levels than intended.
More apixaban in your body means a higher chance of serious bleeding, such as bruising easily, nosebleeds, blood in your urine or stool, or worse. Because of this risk, using these two together is not recommended. The good news: your doctor and pharmacist can plan around this, so please talk with them before starting either drug.
Direction: Ensitrelvir inhibits both CYP3A4 and P-glycoprotein. Apixaban is a substrate of both pathways (it is not a prodrug), so combined inhibition is expected to raise apixaban AUC and Cmax, increasing bleeding risk.
- Severity: Contraindicated combination.
- Evidence: Theoretical; magnitude not quantified.
- Onset: Unspecified.
- Management: Avoid co-administration. If ensitrelvir is being started, evaluate clinical and PK factors first. When reinitiating apixaban, account for the duration of residual CYP3A/P-gp inhibition and patient-specific bleeding risk. Monitor closely for signs of bleeding if exposure occurs.
What happens
Increased CYP3A/P-gp substrate exposure and an increased risk of adverse reactions
Interaction Deep Dive
Giving ensitrelvir together with agents that act as substrates for both CYP3A and P-gp is contraindicated, because doing so can raise the exposure of those CYP3A/P-gp substrates, which may in turn produce severe, life-threatening, or fatal outcomes stemming from the elevated substrate exposure. Ensitrelvir should be started only after the relevant clinical and pharmacokinetic characteristics of the co-administered drug have been carefully weighed. Furthermore, decisions to restart contraindicated CYP3A substrates should be guided by how long CYP3A inhibition is expected to persist along with factors specific to the individual patient1.
Why it happens (mechanism)
Inhibition of P-gp-mediated efflux transport by ensitrelvir; inhibition of CYP3A-mediated metabolism by ensitrelvir
How to manage this interaction
These two are generally not used together. Your care team is the one to make any changes, so keep taking your medications as prescribed and reach out before starting either one.
- Tell your prescriber and pharmacist that you take apixaban (Eliquis) before any ensitrelvir is started.
- Your team may hold, adjust, or delay one medication, and will time restarting apixaban based on how long the antiviral keeps affecting your body.
- Watch for and promptly report bleeding signs: unusual bruising, nosebleeds, pink or red urine, black or bloody stools, or bleeding that will not stop.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
2 reports — tap to read
a) Giving ensitrelvir (a single 500 mg dose, which is not a recommended ensitrelvir dosage) together with a single oral dose of a transporter cocktail that included 0.25 mg digoxin produced a 2.17-fold rise in the Cmax and a 1.31-fold rise in the AUC(0 to inf) of digoxin 1.
b) Giving midazolam (a CYP3A substrate) as a single 2 mg oral dose together with ensitrelvir at the clinical dose (375 mg on day 1 and 125 mg on days 2-5) on Day 5 produced an approximately 2.80-fold rise in the Cmax and a 6.77-fold rise in the AUC(0 to inf) of midazolam compared with midazolam given by itself. In addition, giving dexAMETHasone (a single 1 mg dose) together with ensitrelvir (750 mg on day 1 and 250 mg on days 2-5, twice the recommended dose) on day 5, and giving it alone on day 9 (5 days after the final ensitrelvir dose) and day 14 (10 days after the final ensitrelvir dose), produced an approximately 1.47-fold rise in Cmax and a 3.47-fold rise in AUC(0 to inf) of dexAMETHasone on day 5, a 1.24-fold rise in Cmax and a 2.38-fold rise in AUC(0 to inf) on day 9, and a 1.17-fold rise in Cmax and a 1.58-fold rise in AUC(0 to inf) on day 14, compared with dexAMETHasone given by itself 1.
Common questions
Can I take Ensitrelvir and Apixaban together?
Apixaban and ensitrelvir are considered a contraindicated combination because ensitrelvir can raise apixaban levels and bleeding risk. Do not start these together without your doctor or pharmacist planning the timing. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Ensitrelvir and Apixaban interaction?
It is rated contraindicated. These should generally not be used together.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Ensitrelvir and Apixaban interaction managed?
These two are generally not used together. Your care team is the one to make any changes, so keep taking your medications as prescribed and reach out before starting either one. Tell your prescriber and pharmacist that you take apixaban (Eliquis) before any ensitrelvir is started. Your team may hold, adjust, or delay one medication, and will time restarting apixaban based on how long the antiviral… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Ensitrelvir or Apixaban need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: XOCOVA® oral tablets, ensitrelvir oral tablets. Shionogi Inc. Florham Park, NJ, 2026. DailyMed
Keep reading about Apixaban
Keep reading about Ensitrelvir
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist